- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07444866
Gestão Habilitada por Aprendizagem Automática da Intervenção para Sintomas Comportamentais e Psicológicos da Demência para Cuidadores de Demência
Desenvolvimento e Teste de uma Intervenção de Gestão dos Sintomas Comportamentais e Psicológicos da Demência com Aprendizagem Automática para Cuidadores de Demência: Um Estudo de Desenho Experimental Híbrido
Develop and test a machine learning enabled management of behavioural and psychological symptoms of dementia intervention for dementia caregivers.
Visão geral do estudo
Status
Condições
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Hong Kong, Hong Kong
- The Education University of Hong Kong
-
Contato:
- Kee Lee Chou, PhD
- Número de telefone: +85229487473
- E-mail: klchou@eduhk.hk
-
Contato:
- Vivien Tang, MSc
- E-mail: s1135125@s.eduhk.hk
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- aged 18 above
- family caregiver of an individual with a confirmed medical diagnosis of any type of dementia who has been residing in the community
- having been providing care for ADLs and IADLs for at least 20 hours per week for at least one year prior to recruitment
- have a smartphone
- have mild to moderate stress (the 14-item Chinese version Perceived Stress Scale).
Exclusion Criteria:
- having participated in any structured mind-body intervention, cognitive therapy, or structured psychosocial intervention in the 6 months prior to recruitment
- having acute psychiatric and medical comorbidities that are potentially life-threatening (e.g. suicidal ideation) or that limit the caregivers' participation or adherence (e.g. acute psychosis)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição fatorial
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Active control
Active control |
No APP based coaching, no human coaching, no rerandomization, no MRT |
|
Experimental: App & Human Coaching + Continue Intervention
First-line of coaching: App + Human Coaching Responder |
Continue with existing intervention plan |
|
Experimental: App & Human Coaching + Increase intensity in human coaching
First-line of coaching: App + Human Coaching Non-Responder |
Increase intensity of human coaching |
|
Experimental: App & Human Coaching + Booster
First-line of coaching: App + Human Coaching Non-Responder |
Add a booster session |
|
Experimental: App Coaching + Continue Intervention
First-line of coaching: App Coaching Responder |
Continue with existing intervention plan |
|
Experimental: App Coaching + Increase intensity in human coaching
First-line of coaching: App Coaching Non-Responder |
Increase intensity of human coaching |
|
Experimental: App Coaching + Booster
First-line of coaching: App Coaching Non-Responder |
Add a booster session |
|
Experimental: Human Coaching + Continue Intervention
First-line of coaching: Human Coaching Responder |
Continue with existing intervention plan |
|
Experimental: Human Coaching + Increase intensity in human coaching
First-line of coaching: Human Coaching Non-Responder |
Increase intensity of human coaching |
|
Experimental: Human Coaching + Booster
First-line of coaching: Human Coaching Non-Responder |
Add a booster session |
|
Experimental: No Coaching + Continue Intervention
First-line of coaching: No Coaching Responder |
Continue with existing intervention plan |
|
Experimental: No Coaching + Increase intensity in human coaching
First-line of coaching: No Coaching Non-Responder |
Increase intensity of human coaching |
|
Experimental: No Coaching + Booster
First-line of coaching: No Coaching Non-Responder |
Add a booster session |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Stress
Prazo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
10-item Perceived Stress Scale; each item will be rated from 0=Never to 4=Very often. Total scores range from 0 to 40. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Depression
Prazo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Patient Health Questionnaire-9; Each item will be rated from 0=Not at all to 3=nearly everyday. Total scores range from 0 to 27 |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Sleep Quality
Prazo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Pittsburgh Sleep Quality Index; each item will be rated from 0=No difficulty to 3=Severe difficulty. Total scores range from 0 to 21. Higher scores indicating poorer sleep quality |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Anxiety
Prazo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Generalised Anxiety Disorder; each item will be rated from 0=not at all to 3=nearly every day. Total score range from 0 to 21. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Physical Health
Prazo: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Lawton Instrumental Activities of Daily Living; each item will be rated 0=dependent to 1=independent. Total scores range from 0 to 8. |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Physical Health
Prazo: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Activities of Daily Living; each item will be rate from 0=dependent to 5/10=independent. Total scores range from 0 to 100. |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Physical Symptoms
Prazo: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Wahler Physical Symptoms Inventory; each item will be rated from 0=almost never agree to 5=agree almost every day. Total score range from 0 to 210. |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Chronic Illness
Prazo: Baseline (T0), 32 weeks after baseline assessment (T4)
|
Participants will indicate any presence of chronic illness (e.g., diabetes, asthma, high blood pressure). |
Baseline (T0), 32 weeks after baseline assessment (T4)
|
|
Caregiver Burden
Prazo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
12-item Zarit Burden Interview Scale ; each item will be rated from 0=Never to 4=Nearly always. Total scores range from 0 to 48. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Psychological Well-Being
Prazo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
18-item Ryff Psychological Well-Being scale, each item range from 1-strongly agree to 7-strongly disagree. Total score range from 18-126. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Physical and Mental Health
Prazo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
5-level EQ-5D version (EQ-5D-5L) will be utilized; the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ VAS records the patient's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative measure of health outcome that reflects |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Neuropsychiatric
Prazo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Neuropsychiatric Inventory Questionnaire; classified each of the 12 domain into presence of symptom, frequency, severity, and caregiver distress. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
|
Memory and Behaviour Problems
Prazo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Revised Memory and Behavior Problems Checklist; a 24-item checklist from 0=never occurred/not at all to 4=daily/extremely. Higher score indicate more frequent behavioral problems/caregiver distress |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Caregiving
Prazo: Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Revised Scale for Caregiving Self-efficacy; 15-item scale. Total score is 100. |
Baseline (T0), 6 weeks after baseline assessment (T1), 10 weeks after baseline assessment (T2), 20 weeks after baseline assessment (T3), 32 weeks after baseline assessment (T4)
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Kee Lee Chou, PhD, The Education University of Hong Kong
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- 2023-2024-0387
- 22231921 (Número de outro subsídio/financiamento: Research Fund Secretariat, Health Bureau)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .